1h Free Analyst Time
T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 6 and 1 respectively. Similarly, the universities portfolio in Phase 0 stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Solid Tumor, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Multiple Sclerosis, Rheumatoid Arthritis, Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Colon Cancer, Colorectal Cancer, Gastrointestinal Radiation Toxicity, Hemophagocytic Lymphohistiocytosis, Inflammatory Bowel Disease, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Skin And Soft Tissue Infections, Stem Cell Transplantation, Systemic Lupus Erythematosus and Uveitis.
Furthermore, this report also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
Alpine Immune Sciences Inc
Atox Bio Ltd
Avacta Life Sciences Ltd
Bristol-Myers Squibb Co
Five Prime Therapeutics Inc
Imugene Ltd
OSE Immunotherapeutics
Regeneron Pharmaceuticals Inc
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
ALPN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALPN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Target ICOS, CD28 and NCR3LG1 for Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lulizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Agonize CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-5678 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Alpine Immune Sciences presents ALPN-101 phase 1 healthy volunteer study data and details of upcoming phase I/II BALANCE GVHD study at the 61st American Society of Hematology annual meeting
Nov 12, 2019: Alpine Immune Sciences presents new ALPN-101 preclinical data at the 2019 American College of Rheumatology (ACR) Annual Meeting
Nov 09, 2019: Five Prime Therapeutics presents initial safety data from the phase 1 trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting
Nov 08, 2019: Alpine Immune Sciences presents new preclinical data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Nov 06, 2019: Alpine Immune Sciences announces oral presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition
Oct 30, 2019: Alpine Immune Sciences completes enrollment of phase I study of ALPN-101 and announces third quarter conference call
Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation of ALPN-101 at ACR/ARHP 2019 Annual Meeting
Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation on ALPN-202 at SITC 2019 Annual Meeting
Jun 18, 2019: Atox Bio announces exercise by BARDA of next option period to support continued development of reltecimod for NSTI
Apr 09, 2019: OSE Immunotherapeutics announces issuance of Canadian patent and notice of allowance of U.S. patent protecting CD28-Antagonist Immunotherapy FR104
Feb 19, 2019: Alpine Immune Sciences presents preclinical ALPN-101 GvHD data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)
Feb 14, 2019: Atox Bio announces appointment of Robert Greif as chief commercial officer
Feb 12, 2019: Alpine Immune treats first patient in Phase I trial of ALPN-101
Dec 03, 2018: Alpine Immune sciences showcases key preclinical data at 60th American Society of Hematology Annual Meeting and Exposition
Nov 29, 2018: Alpine Immune Sciences announces ALPN-101 data to be included in oral presentation at 60th American Society of Hematology Annual Meeting and Exposition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alpine Immune Sciences Inc, H2 2019
Pipeline by Atox Bio Ltd, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Five Prime Therapeutics Inc, H2 2019
Pipeline by Imugene Ltd, H2 2019
Pipeline by OSE Immunotherapeutics, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by TheraMAB LLC, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alpine Immune Sciences Inc
- Atox Bio Ltd
- Avacta Life Sciences Ltd
- Bristol-Myers Squibb Co
- Five Prime Therapeutics Inc
- Imugene Ltd
- OSE Immunotherapeutics
- Regeneron Pharmaceuticals Inc
- TheraMAB LLC
